Citations

Clear

1792 citation(s) found for "Stephanie".

Visualizing the US News & World Report Prostate Cancer Surgery Rating: Developing a Coherent Cohort
Anderson, Stephanie S., Pickering, Elizabeth, Vaver, Anne M, Dalvi, Jay R., Pollock, Benjamin D , Dalvi, Jay, Pollock, Benjamin D. , Braswell-Pickering, Elizabeth , Lyon, Timothy D.

Mayo Clinic

Urology Practice | March 26, 2026 | Volume: 13 | Issue: 4 | Pages: 367-374

10.1097/upj.0000000000001006 | PMID 41886404 Get It

Bridging the Hospital Discharge Gap: Pilot Trial of a Digital Smoking Cessation Program for Psychiatric Inpatients
Bennett, Melanie E. , Dickerson, Faith , Cha, Sarah , Brandler, Brian J., Lucksted, Alicia , Medoff, Deborah , Marano, Christopher , Knight, Stephanie, Medoff, Deborah R. , Graham, Amanda L.

Mayo Clinic

Psychiatric Services | March 26, 2026 | Volume: 77 | Issue: 5 | Pages: 421-428

10.1176/appi.ps.20250326 | PMID 41881842 Get It

NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas
Butt, Omar H. , Singhal, Kartik , Luo, Jingqin , Rettig, Michael P. , Foltz, Jennifer A. , Huang, Jiayi , Zhou, Alice Y. , Tao, Yu , Griffith, Obi L., Griffith, Malachi, Johanns, Tanner M. , Ansstas, George , Zhang, Chaocai , Tang, Justin , Christ, Stephanie , Ferrando-Martinez, Sara , Lee, Byung Ha , Chheda, Milan G., Fehniger, Todd A. , Campian, Jian L., Griffith, Malachi , Griffith, Obi L. , Huang, Jiayi , Griffith, Obi L , Griffith, Malachi , DiPersio, John F , Chheda, Milan G , Fehniger, Todd A , Campian, Jian L , Luo, Jingqin , Ansstas, George , DiPersio, John F. , Chheda, Milan G. , Campian, Jian

Mayo Clinic

Clinical Cancer Research | March 25, 2026 | Volume: 32 | Issue: 13 | Pages: 2581-2592

10.1158/1078-0432.ccr-25-2953 | PMID 41880597 Get It

Abstract Purpose: Standard care for high-grade gliomas (HGG) involves maximal surgical resection followed by radiation and temozolomide. Postoperative adjuvant therapy frequently causes lymphopenia, which is associated with poor prognosis. Interleukin 7 (IL7) is essential for lymphocyte development, homeostasis, and survival. NT-I7 (efineptakin alfa), a long-acting recombinant IL7, reverses lymphopenia and improves survival in murine glioma models. However, the safety, maximum tolerated dose (MTD), and impact of NT-I7 on immune cells in patients with HGG remain unknown. Patients and Methods: We conducted a phase I trial (NCT03687957) examining the MTD and effect of NT-I7 on lymphocytes in patients with newly diagnosed HGG. The primary endpoint was dose-limiting toxicity; secondary endpoints included absolute lymphocyte count (ALC) changes over time, overall response, progression-free survival, and overall survival. Exploratory endpoints included immune profiling at different time points using single-cell RNA sequencing (scRNA-seq) in a subset of patients. Results: NT-I7 was well tolerated with a MTD of 720 µg/kg. Moreover, NT-I7 significantly increased ALCs for more than 12 weeks in duration. Early elevations in CD4+, CD8+ T cells and NK cells further coincided with increased TNF and CXCL9 cytokine levels. Comprehensive immune profiling of peripheral blood T cells revealed selective clonotype expansion within CD8+, but not CD4+, T cells following NT-I7 administration. Finally, a subset of our patients with MGMT promoter–unmethylated glioblastoma, which are typically associated with a poorer prognosis, demonstrated promising clinical responses. Conclusions: NT-I7 has the potential to maintain and increase lymphocyte counts in patients with HGG and warrants further investigation, particularly in combination with immune-based therapies.
Perioperative low molecular weight heparin bridging in aortic mechanical heart valve patients undergoing endoscopic procedures
Grewal, Tegvir Singh, Godoy, Alejandro , Bhagirath, Vinai, Casanegra, Ana I, Tafur, Alfonso , Fontani, Amelia McNiven, Houghton, Damon E, Galanaud, Jean-Philippe, Sordo, Luigi D, Alnuaimi, Mouza, Daniels, Paul R, Sadozai, Yama, Douketis, James, Godoy, Alejandro Daniel , Ghorbanzadeh, Atefeh , Barkun, Alan N , Grewal, Tegvir, Bhagirath, Vinai C. , Casanegra, Ana I. , Houghton, Damon E. , Abdulrehman, Jameel , Galanaud, J.‐P. , Sordo, Luigi Del, Daniels, Paul R. , Carlin, Stephanie , Barkun, Alan , Douketis, James D.

Mayo Clinic

Endoscopy International Open | March 24, 2026 | Volume: 14 | Issue: CP | Pages: No page available

10.1055/a-2840-7302 | PMID 42016519 Get It

Abstract Optimal management of anticoagulation for patients with aortic mechanical heart valves (MHVs) receiving vitamin K antagonists (VKAs) undergoing gastrointestinal endoscopic procedures is clinically challenging. Risk of bleeding from an unanticipated polypectomy or biopsy further complicates this issue. Current guidelines on use of bridging with low-molecular-weight heparin (LMWH) for these procedures are based on low-quality evidence. We conducted a subanalysis of a retrospective, multicenter observational study of adult patients with aortic MHVs receiving VKAs who underwent elective gastrointestinal endoscopies (colonoscopy or upper endoscopy). We included patients who underwent the procedure between July 1, 2020, and July 1, 2023, at five centers in Canada and the United States Patients with procedures performed on separate days within a 30-day period were excluded. Efficacy and safety outcomes included thromboembolic events, major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) in the 30 days post procedure. A total of 192 endoscopic procedures were analyzed. Median (interquartile range [IQR]) patient age was 66 years (58.2–72.8) and 22% were female. Warfarin was interrupted for 185 procedures (96%). Among these, 119 (64%) received LMWH bridging: 33 (17%) pre-procedure only, 10 (5%) post-procedure only, and 76 (40%) both pre- and post-procedure. Post-procedure LMWH was initiated a median (IQR) of 1 day (1–1) and discontinued 5 days post-procedure (3–8). MB occurred in two patients (1%), CRNMB in two patients (1%), and one death (0.5%) was identified; no thromboembolic events occurred. Prior to propensity score matching (PSM), post-procedure LMWH with or without pre procedure LMWH was associated with the composite outcome of MB and CRNMB (P = 0.034), although not with MB or CRNMB individually. After stepwise regression and PSM analyses, no significant differences in bleeding outcomes were observed between patients who received LMWH bridging and those who did not. Our findings indicate that although adverse thrombotic events were rare and use of post-procedure LMWH bridging was significantly associated with a small absolute increased risk of bleeding, it was not significant after PSM. Larger prospective studies are needed to better inform antithrombotic management guidelines for patients with aortic MHVs undergoing gastrointestinal endoscopy.
269: PROTOCOL FOR COMPASSIONATE DEACTIVATION OF MECHANICAL CIRCULATORY SUPPORT IN THE ICU
Carmon, Stephanie, Sanghavi, Devang, He, Ruina, Nobles, Patrick, Sanghavi, Devang, He, Ruina

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001183072.36259.c9 Get It

Long COVID Syndrome and Associated New Daily Persistent Headache ( NDPH ) Presenting With Crossed Clonus Response
Wetmore, Emma , Wetmore, Emma , Grach, Stephanie, Grach, Stephanie L. , Boes, Christopher J. , Lanzino, Giuseppe , Kissoon, Narayan

Mayo Clinic

Clinical Case Reports | March 20, 2026 | Volume: 14 | Issue: 3 | Pages: No page available

10.1002/ccr3.72386 | PMID 42016647 Get It

ABSTRACT Evaluating patients following a COVID‐19 infection with multiple chronic, progressive symptoms can be challenging, but easy to navigate by using the temporal profile obtained from the clinical history, findings from the neurological exam, and screening for red flag symptoms.
Utility of the Early Sjögren Antibody Panel as a Diagnostic Marker for Sensory Neuropathy
Zeidman, Lawrence A. , Fawaz, Cherine N., Phillips, Stephanie Gordon, Latack, Katie, Fawaz, Cherine , Phillips, Stephanie

Mayo Clinic

Muscle & Nerve | March 17, 2026 | Volume: 73 | Issue: 6 | Pages: 1146-1150

10.1002/mus.70204 | PMID 41839642 Get It

ABSTRACT Introduction/Aims:. Primary Sjögren syndrome (SS) is a chronic autoimmune disease characterized frequently by sensory neuropathy (SN). Carbonic Anhydrase‐6 (CA‐6), Parotid Secretory Protein (PSP), and Salivary Protein‐1 (SP‐1) antibodies (Early Sjögren antibodies [ESA]) are found in 45% of SS patients who lack traditional antibodies (Ro/La). But there is a lack of information regarding whether ESA are associated with SN, and if there are any identifying characteristics associated with ESA in SN. Our goal was to close this knowledge gap. Methods All SN patients tested for ESA from May 2023–October 2024 were retrospectively analyzed for clinical features such as sicca symptoms, onset acuity, small fiber neuropathy (SFN)‐questionnaire scores, and pathological features such as length‐dependence/vasculitis on skin biopsies, as well as lip biopsy confirmation of SS. Seropositive/seronegative groups were separated for statistical analysis. Results Thirty‐three adult patients (73% female) with cryptogenic SN had ESA testing. Eighteen (55%) had abnormal ESA. Twelve (100%) seropositive patients had significant sicca symptoms versus four seronegative patients (29%) ( p = 0.0002). There were no significant associations between ESA seropositivity and SFN‐questionnaires, pathological nonlength dependence (NLD)/vasculitis, or onset acuity. Discussion ESA may be seen in more than half of cryptogenic SN patients, but whether these patients have confirmed SS is unclear. Seropositive patients more frequently have significant sicca symptoms than seronegative patients, but no other significant identifying characteristics were seen. Further work on a larger population should be done to confirm these findings, but this study suggests the utility of checking ESA in cryptogenic SN patients with significant sicca symptoms.
Translating AI research into reality: summary of the 2025 voice AI Symposium and Hackathon
Cruz, Samantha Salvi, Toghranegar, Jamie , MacDonald, Bob, Speights, Marisha, Noufi, Camille , Fagherrazi, Guy, Blatter, Alden, Arienzo, Arianna, Baur, Sebastien , Wetstone, Katie , Peller, Julian, Au, R., Botha, Hugo, Lahav, Amir, Hemmerling, Daria , Anibal, James, Coleman, Oita C, Gallois, Hortense , Martinez, Sophia Avila, Mahapatra, Nihar R. , Sara, Jaskanwal Deep Singh , Mathur, Aarush, Patel, Rupal , Zieliński, Konrad , Lerner-Ellis, Jordan, Cong, Yan , Ngo, Hoan, Talkar, Tanya , Hale, Greg, Comito, Keith, Ghosh, Satrajit, Watts, Stephanie, Powell, Maria, Bélisle-Pipon, Jean-Christophe, Krussel, Andrea, Mahapatra, Ishaan, Bahr, Ruth Huntley , Kostelnik, Cynthia, Dorsey, Katie, John, MyVan, Curp, Kathleen, Rameau, Anaïs, Bensoussan, Yaël , Singh Sara, Jaskanwal Deep, Hemmerling, Daria , Cruz, Samantha Salvi, Malin, Bradley , Mehra, Tarun , Speights, Marisha L., Fossat, Yan , Cummins, Nicholas , Elbeji, Abir , Gelbard, Alexander , Au, Rhoda , Botha, Hugo, Lahav, Amir, Catania, Fabio , Saha, Shumit , Kourtis, Lampros C , Lerner‐Ellis, Jordan P. , Watts, Stephanie, Bedrick, Steven , Belisle-Pipon, Jean-Christophe , Krussel, Andrea, Mahapatra, Ishaan , Hanna, Karim , Rameau, Anais

Mayo Clinic

Frontiers in Digital Health | March 16, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fdgth.2026.1754426 | PMID 41918982 Get It

The 2025 Voice AI Symposium represented a transition from conceptual research to clinical implementation in vocal biomarker science. Hosted by the NIH-funded Bridge2AI-Voice consortium, the meeting convened global experts to address the methodological, ethical, and translational challenges of integrating voice-based artificial intelligence (AI) into healthcare. This mini-review synthesizes symposium insights across six domains: multimodal integration, FAIR (Findable, Accessible, Interoperable, Reusable) and CARE (Collective Benefit, Authority to Control, Responsibility, Ethics) data governance, clinical translation, interdisciplinary training, and cross-sector innovation. Research presented demonstrated voice as a latent, multimodal biomarker reflecting neurological, cardiopulmonary, and psychological states, while discussions emphasized ethical data practices and human-centered design. The implementation-focused panels underscored the importance of workflow alignment and usability for adoption in real-world care. Collectively, the symposium reflects a field advancing toward translational readiness and ethical accountability, positioning voice AI as a scalable, inclusive tool for next-generation healthcare.
Program interventions to build access to living donor transplantation
Yi, Stephanie G. , Mathur, Amit K. , Woelfel, Ingrid, Woelfel, Ingrid A.

Mayo Clinic

Current Opinion in Organ Transplantation | March 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mot.0000000000001277 | PMID 41830422 Get It

Purpose of review Living donor transplantation is the optimal treatment for end-stage renal disease and end-stage liver disease. For the recipient, the benefits of living donation include improved duration of graft survival compared to deceased donation and avoidance of lengthy waiting time and risks of dialysis. For transplant centers, a robust living donor program results in consistent transplant case volumes, daytime cases and a decreased reliance on potentially unfavorable allocation policy changes. Transplant programs require a playbook of actionable initiatives based on consensus best practices and peer-reviewed data to optimize opportunities to increase living donor evaluation and surgery within current legal and policy frameworks. Relevant findings Strategies to increase center living donor volume include utilization of culturally competent transplant education and outreach, development of living donor champion programs, wider utilization of financial assistance programs available to living donors, increased enrollment in paired donor exchange services and adaptation of modern evidence-based selection and evaluation criteria. Summary Understanding the current landscape of living donor transplantation and exploring areas of innovation is imperative to a center's ability to continue to serve the full spectrum of patients with end stage organ disease to the best of our collective ability.
Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis
Dabaja, Bouthaina S., Görlich, Dennis , Thomas, Bjorn , Sim, Van , Johnstone, P., Hashmi, Ayesha, Levis, M., Ackerson, Bradley, Hague, Christina J. , Roos, Daniel Edward, Kirova, Y., Fietkau, Rainer, Fang, Penny Q., Ng, A., Bock, Felix, Linde, Philipp , Dunst, Jürgen, Terezakis, Stephanie A, Easwaran, Teresa, Peeken, Jan C. , Wittig, Andrea, Yoon, Hong In , Illidge, Tim , Ricardi, U., Morris, S., Storck, Michael , Hoppe, Richard T, Eich, Hans Theodor, Hoppe, Richard T. , Levis, Mario , Oertel, Michael , Görlich, Dennis , Thomas, Bjorn R , Sim, Van , Levis, Mario , Weil, Christopher R , Bock, Felix , Peeken, Jan C , Yoon, Hong In , Tao, Randa , Binkley, Michael Sargent , Campbell, Belinda A , Elsayad, Khaled , Storck, Michael , Hoppe, Richard T , Hashmi, Ayesha , Weil, Christopher R. , Plastaras, John Peter , Roos, Daniel E. , Fietkau, Rainer , Fang, Penny , Tseng, Yolanda D. , Tao, Randa , Kelsey, Chris R. , Binkley, Michael S. , Eich, Hans Theodor

Mayo Clinic

Blood | March 13, 2026 | Volume: 147 | Issue: 25 | Pages: 3051-3060

10.1182/blood.2025032050 | PMID 41824381 Get It

Abstract Radiotherapy is an established treatment for low-grade primary cutaneous B-cell lymphoma. Recommendations on its use differ internationally, which prompted our group to conduct this analysis. Twenty-two institutions participated in this international study. Patient eligibility required a diagnosis of limited (T1/T2) primary cutaneous marginal zone or follicle center lymphoma treated with radiotherapy between 1995 and 2023. Data were collected retrospectively until February 2024 within the framework of the International Lymphoma Radiation Oncology Group. Overall, 535 patients were analyzed. Predominant locations were the head (40%) and trunk (36%). Radiotherapy had a median dose of 24 Gy in fractions of 2 Gy. Complete responses were observed in 91% at a median time of 3.6 months following radiotherapy. There was no statistically significant difference between treatments ≤4 Gy and >4 Gy for complete or overall response rates (P = .077 and P = .056, respectively). However, there was an inferior duration of local control with ≤4 Gy (5-year local control 73% ± 12% vs 96% ± 2%; P< .001). Radiation dose was the main prognostic factor in the univariate and multivariable Cox analysis; however, higher doses did not translate into an overall survival benefit. Toxicities rarely exceeded grade 2 but were more frequent in the >4 Gy group. Radiotherapy remains an effective treatment option for indolent skin lymphoma with low toxicity. High response rates are observed with low doses of ≤4 Gy. In comparison to conventional doses, these treatments have a shorter duration of local control but a favorable toxicity profile.